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RADIATION DOSE MAPPING OF THE STOMACH IN TRIMODALITY 
THERAPY FOR ESOPHAGEAL CANCER  
Andrew Bang, Joel Broomfield, Sebastien Gilbert, Jason 
Pantarotto 
The Ottawa Hospital Cancer Centre, Ottawa, ON 
Purpose: Esophageal cancer remains a difficult cancer to cure 
despite aggressive therapy. A common strategy aimed at 
achieving cure in locally advanced esophageal cancers is to use 
neoadjuvant concurrent chemoradiotherapy followed by surgery 
(“trimodality” therapy). Post-operative complications following 
esophagectomy with gastric pull-up are significant events when 
they occur, including possible anastomotic leaks. Our goal is to 
investigate whether a relationship exists between these 
complications and radiation dose to either anastomotic end 
(proximal esophageal and distal gastric). For this purpose, we 
present dosimetric data describing the planned dose to different 
parts of the stomach with specific attention paid to the distal 
2/3 of the organ which is most commonly used to form the 
gastro-esophageal anastomosis. 
Methods and Materials: An ethics board-approved retrospective 
analysis was performed on 37 consecutive patients at our 
institute who underwent neoadjuvant chemoradiotherapy 
followed by a radical esophagectomy. Patients were treated 
between January 1, 2008 and December 31, 2012. For each case, 
the 3D conformal plan was re-calculated once the stomach was 
contoured. Gastric contouring consisted of an overall organ 
contour from the gastro-esophageal junction to the pylorus. A 
series of sub-contours were then devised dividing the stomach 
into thirds: superior, middle and inferior third. The superior third 
was further subdivided into medial and lateral sub-components. 
At the time of simulation, patients were not given any specific 
instructions for food avoidance, and a subset were asked to drink 
oral contrast (< 100 ml). The mean radiation dose and V40 were 
computed for specified regions of the stomach. 
Results: A total of 37 patients were analyzed. The study cohort 
included 31 cases of esophageal adenocarcinoma and six cases of 
squamous cell carcinoma. Thirty-five of 37 cases involved the 
lower third of the esophagus. All surgeries were performed with 
a transthoracic approach, with minimally invasive (15) or open 
techniques (22). Radiation dose varied between 4500-5040 cGy, 
given 180-200 cGy per day, often with a two phase approach with 
a smaller boost volume. The mean (range) dose of the medial 
superior, lateral superior, middle and inferior thirds of the 
stomach were 3919 cGy (46–5193), 2587 cGy (40–5077), 2569 cGy 
(27–4713) and 1304 cGy (14–4265) respectively. The calculated 
V40 for each gastric sub-segment was 72.3%, 34.0%, 34.7% and 
12.5% respectively. 
Conclusions: There is no radiation sparing of the distal 2/3 of 
the stomach in patients treated with neoadjuvant radiotherapy 
for esophageal cancer. In some cases, doses approach or are 
equal to the prescribed dose. Surgeons may not be aware that 
tissues used to form an anastomosis with the proximal esophagus 
may have received significant dose. There is rationale to 
investigate a relationship between dose to the stomach and 
potential anastomotic complications in this patient population. 
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RADIUM-223 IN METASTATIC CASTRATION-RESISTANT PROSTATE 
CANCER: SINGLE-INSTITUTION ANALYSIS OF FACTORS 
ASSOCIATED WITH TREATMENT COMPLETION AND SURVIVAL  
Andrew Bang, Shawn Malone, Eugene Leung, Christina Canil, 
Libni Eapen, Scott Morgan 
The Ottawa Hospital Cancer Centre, Ottawa, ON 
Purpose: Radium-223 (Ra-223), an alpha particle-emitting 
radionuclide, is the first bone-targeted therapy demonstrated to 
improve survival in metastatic castration-resistant prostate 
cancer (mCRPC). We report our institution’s experience with this 
therapy, exploring the association between mCRPC therapies 
received prior to Ra-223 and treatment outcomes. 
Methods and Materials: The outcomes of patients with 
progressive, symptomatic mCRPC with bone metastases treated 
with Ra-223 between October 2009 and December 2015 were 
analyzed. The association between baseline characteristics and 
outcomes following treatment were analyzed using descriptive 
statistics while overall survival (OS) was estimated using the 
Kaplan-Meier method. Toxicities were assessed using NCI CTCAE 
v4.0. 
Results: A total of 36 patients were analyzed. Median follow up 
was 6.8 months (range, 1.5-34.7). Median age was 75 years 
(range, 49-88). Prior to commencing Ra-223, 14 patients (39%) 
were treated with abiraterone acetate (abi), 17 patients (47%) 
with enzalutamide (enza), and 14 patients (39%) with docetaxel; 
16 patients (44%) received more than one of these agents and 
seven (19%) received none. The median number of Ra-223 
injections received was five (range, 1-6). Nineteen patients 
(53%) discontinued therapy prematurely. Median OS for the total 
cohort was 10.0 months (95% CI, 4.5-15.0). There was a non-
significant trend towards shorter OS in those patients that had 
received prior abi or enza versus those that had previously 
received neither of these agents (median 6.8 versus 14.0 months; 
HR 2.67; 95% CI, 0.87-8.20; log-rank p = 0.087). Forty-four 
percent of patients that had received prior abi/enza completed 
all six planned injections of Ra-223 versus 55% of those that had 
not received prior abi/enza. There were differences in the 
baseline characteristics of those that had received prior abi/enza 
versus not: mean PSA 272 versus 114 mcg/L, and proportion with 
≥ 20 metastases 64% versus 44%, respectively. Cumulative 
incidence of Grade ≥ 3 hematologic toxicity during or after 
treatment with Ra-223 was as follows: anemia 19%, neutropenia 
0%, and thrombocytopenia 11%. 
Conclusions: This cohort of patients receiving Ra-223 spans the 
era prior to the advent of abi and enza and thus included patients 
with and without prior exposure to these agents. Patients 
receiving abi and/or enza prior to commencing Ra-223 were less 
likely to complete the 6 planned injections and had a non-
significant trend toward shorter survival, raising the hypothesis 
that earlier integration of Ra-223 in the mCRPC disease course 
may be preferred. This apparent association may simply reflect 
greater disease burden in more heavily pre-treated patients 
rather than diminished efficacy of Ra-223 in this setting. 
Prospective trials of Ra-223 in early mCRPC are underway. 
Finally, the toxicity profile of Ra-223 observed in this real-world 
setting was relatively favourable and comparable to that seen in 
the Phase III trial that led to regulatory approval. 
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ADJUVANT RADIOTHERAPY FOR PROSTATE CANCER: DID GUROC 
RECOMMENDATIONS INFLUENCE PRACTICE TRENDS? 
Wei Ning (Will) Jiang1, Amandeep Taggar1, Majed Alghamdi1, 
Derek Tilley2, Xanthoula Kostaras3, Marc Kerba1, Siraj Husain1, 
Geoff Gotto4, Michael Sia5 
1Tom Baker Cancer Centre, Calgary, AB 
2Cancer Control Alberta, Calgary, AB 
3University of Alberta, Edmonton, AB 
4 University of Calgary, Calgary, AB  
5British Columbia Cancer Agency, Abbotsford, BC 
Purpose: In 2008, the Genito-Urinary Radiation Oncologist of 
Canada (GUROC) published a guideline recommending adjuvant 
RT (aRT) for the treatment of prostate cancer patients with high-
risk features (HRF; positive margins, extracapsular extension 
[ECE], or seminal vesicle invasion [SVI]). To determine the 
association between the guideline and the patterns of practice, 
we compared the rate of aRT offered prior to and following this 
GUROC recommendation. 
Methods and Materials: All patients treated with 
radical prostatectomy (RP) in 2005 (pre-GUROC cohort) and 
2012 (post-GUROC cohort), who were eligible for aRT (HRF 
and post-operative PSA < 0.2ng/mL) and were referred to a 
radiation oncologist in a particular Canadian province were 
identified retrospectively from the cancer registry. 
Demographics, pathology, commodities, and treatment data 
were extracted from patients’ electronic medical record. 
aRT was defined as radiation given within six months of RP 
with the last PSA before 
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radiotherapy < 0.2 ng/mL. Salvage RT was defined as radiation 
delayed until PSA rose above a threshold (≥ 0.2ng/mL). All 
patients were followed for three years. 
Results: Forty-nine patients (pre-GUROC: n = 20, post-GUROC: n 
= 29) met the inclusion criteria. Age, clinical, and pathological 
factors were similar between the two cohorts, including rates of 
ECE, SVI and post RP PSA (p > 0.05), however, there were more 
patients with positive margins in the post-GUROC cohort (50% 
versus 79%, p = 0.03). Rate of aRT offered was not significantly 
different between the pre- versus post-GUROC cohort, 65% 
versus 69%, (p > 0.05). Furthermore, no differences were noted 
between the rate of salvage RT or no RT offered between the 
cohorts: 15% versus 10% (p > 0.05), and 20% versus 21% (p > 0.05), 
respectively. 
Conclusions: Two-thirds of eligible prostate cancer patients 
referred to radiation oncologists in a particular Canadian 
province were offered aRT. This practice pattern did not 
significantly change after the publication of the GUROC 
recommendations. 
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RADIOTHERAPY OF THE PRIMARY TUMOUR FOR METASTATIC 
PROSTATE CANCER  
Kate Johnson1, Jean Guevara2, Pascal Lambert2, Alexander 
Sachs2, Darrel Drachenberg2, Jeff Saranchuk2, Harvey Quon2 
1University of Manitoba, Winnipeg, MB 
2CancerCare Manitoba, Winnipeg, MB 
Purpose: The standard treatment for men with newly diagnosed 
metastatic prostate cancer (mPCa) is androgen deprivation 
therapy (ADT). Local radiotherapy (RT) to the prostate has 
traditionally been reserved for men who require symptomatic 
relief in patients with metastatic disease. However, local RT may 
have other benefits in addition to symptomatic relief. This study 
investigates the impact of local RT on overall survival (OS) in men 
with newly diagnosed mPCa. 
Methods and Materials: This is a retrospective, population-based 
study of patients age > = 18 years diagnosed with metastatic (M1) 
prostate cancer in Manitoba between 2004-2013. Patients with 
neuroendocrine or small cell histology were excluded. Data was 
collected from Cancer Registry and electronic charts including 
age, T/N/M stage, PSA, Charlson comorbidity score, RT, surgery, 
systemic therapy, Gleason score, and ECOG performance status. 
Cox regression was used to predict OS. Likelihood ratio testing 
was used to identify factors associated with OS. A p value < 0.05 
was considered significant. 
Results: A total of 323 patients were included and 25 (7.7%) 
received RT to the prostate within one year of diagnosis. The 
median follow up was 2.21 years. The mean age was 71.9 years. 
Clinical T stage included T1 (9.3%), T2 (26.6%), T3 (21.7%) and 
T4 (10.5%) and TX (31.9%), N stage ranged from N0 (21.4%), N1 
(37.5%), NX (41.2%). M stages consisted of M1a/M1b (63.5%), M1c 
(14.2%) or MX (22.3%). Of the 25 patients who received prostate 
RT, 15 received high dose (≥ 50 Gy) and 10 low dose (< 50 Gy). 
Multivariable analysis showed a hazard ratio (HR) for death of 
1.09 (95% CI 0.64-1.85, p = 0.75) for patients receiving prostate 
RT (any dose) compared to those without prostate RT. 
Furthermore, the HR for high dose RT was 0.73 (95% CI 0.35-1.53, 
p = 0.41) and 1.77 (95% CI 0.89-3.52, p = 0.1) for low dose RT. 
Conclusions: In this cohort of patients with newly diagnosed 
mPCa, there was no association between RT to the prostate and 
OS. However, this study was limited by statistical power and 
additional investigation in a larger population is needed. 
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ASSESSMENT OF BIOCHEMICAL OUTCOME WITH INCREASING DOSE 
ESCALATION IN LOCALIZED PROSTATE CANCER (PCA) WITH 
PRECISION IMAGE-GUIDED RADIOTHERAPY (IGRT)  
Hamid Raziee1, Jure Murgic1, Melania Pintilie2, Peter Chung1, 
Cynthia Ménard1, Andrew Bayley1, Padraig Warde1, Mary 
Gospodarowicz1, Robert Bristow1, Charles Catton1, Alejandro 
Berlin1 
1University of Toronto, Toronto, ON 
2Princess Margaret Cancer Centre, Toronto, ON 
Purpose:  Dose escalation (DE) increases biochemical and local 
control in PCa. Addition of image guidance improves outcomes 
of highly conformal techniques. However, the benefit of DE and 
optimal fractionation in the context of IGRT remains unknown. 
Herein, we determine biochemical outcomes in three patient 
cohorts treated with progressively DE schemes and daily 
image-guidance (IG). 
Methods and Materials: We analyzed prospectively collected 
data from a single Institution. Departmental standard included 
three sequential prostate-only schedules, A: 75.6 Gy (1.8 Gy/d); 
B: 79.8 Gy (1.9 Gy/d); C: 78 Gy (2 Gy/d). Daily IG consisted of 
fiducial markers and daily orthogonal imaging (predominantly A 
and B) or cone beam CT (mainly C). Patients were categorized 
into NCCN risk categories, and intermediate-risk (IR) subdivided 
into favourable and unfavourable (Zumsteg’s criteria). 
Primary endpoint was biochemical recurrence (BCR) by Phoenix 
definition (PSA nadir + 2 ng/ml). Biochemical relapse-free 
rates (bRFR) were compared between three dose schedules 
and risk groups using Cox proportional hazard models and 
Kaplan-Meier method.
Results: Nine hundred and eighty-seven patients were included 
with a median age of 71.7 years. Risk category distribution was 
18% (low), 68% (IR) and 13% (high). Of IR patients (673), 62% were 
unfavourable. Two hundred and ninety-three (30%), 315 (32%) 
and 379 (38%) patients were treated with A, B and C, 
respectively. Overall, 11% of patients received ADT. Age, initial 
PSA, T-stage, Gleason score, use of ADT and risk 
category distribution were not different between three 
groups. Median follow up was 5.9 years (0.1-16.5): 9.0 years 
(0.1-16.5), 9.6 years (0.1-14.3) and 4.9 years (0.2-9.5) for A, 
B and C. bRFR was significantly different between A, B and C 
(p < 0.0001) with five year rates of 76%, 82%, 91% and eight 
year rates of 54%, 64% and 80%, respectively. Overall, 
compared to C, those treated with A and B had a HR of 2.67 
(95% CI 1.87-3.81, p < 0.001) and 1.93 (95% CI 1.34-2.77, p < 
0.001) for BCR, respectively. In low-risk category, group A 
had a higher risk of BCR compared to C (HR 4.1, 95% CI 
1.18-14.32, p = 0.027), but no difference between B and C was 
observed (p = 0.17). For favourable IR, A and B had increased 
risk of BCR (HR 4.38, 95% CI 1.68-11.4, p = 0.0025 and HR 3.05, 
95% CI 1.18-7.9, p = 0.022, respectively) compared to C. 
Findings were similar for unfavourable IR group (HR 2.24, 95% CI 
1.36-3.67, p = 0.0015 and HR 1.88, 95% CI 1.13-3.14, p = 0.015 
for A and B versus C, respectively). In high-risk category, no 
differences in BCR rates were observed.  
Conclusions:  We observed a possible continuous dose response 
and bRFR improvement with progressive DE in the context of 
daily IG, particularly significant for IR categories. With long-term 
follow up, we observed a continuous occurrence of BCR. Given 
the limitations of retrospective studies, our results justify 
further dosimetric- and technique-related factors analyses. 
Prospective validation of these findings and consideration for 
higher DE-IGRT seem warranted to improve outcomes for PCa. 
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PROGNOSTIC SIGNIFICANCE OF TONSL EXPRESSION AND THE 
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